<DOC>
	<DOCNO>NCT02170077</DOCNO>
	<brief_summary>The purpose study determine efficacy BIA 2 093 treatment epileptic patient refractory simple complex partial seizure without secondary generalization .</brief_summary>
	<brief_title>A Placebo-controlled Study Investigate Safety Efficacy BIA 2-093</brief_title>
	<detailed_description>This clinical trial perform multicentre , add-on , double-blind , randomised , placebo-controlled , phase II study . During double-blind treatment phase ( 12 week ) patient assign three treatment group receive BIA 2 093 daily ( ODG - once-daily group ) , BIA 2 093 twice daily ( TDG - twice-daily group ) placebo ( PLG - placebo group ) , respectively . Daily dose BIA 2 093 increase four-weekly period ( 400 mg , 800 mg 1200 mg ) . On completion 12-week double-blind treatment period , 1-week tapering period schedule .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male female patient age 1865 year Patients simple complex partial seizure without secondary generalization since least one year prior randomisation visit At least 4 seizure per month within last 2 month prior randomisation Stable dose regimen maximum two follow AEDs : phenytoin , valproate , primidone , phenobarbital , lamotrigine , gabapentin , topiramate , clonazepam , 2 month prior randomisation Electroencephalogram ( EEG ) finding contradict epilepsy diagnosis ( e.g. , primarily generalize epilepsy ) Written informed consent . Patient nervus vagus stimulation Patient primarily generalize seizure Known progressive neurological disturbance A history status epilepticus within past 3 month Seizure nonepileptic origin Restricted legal competence incapability follow trial instruction Major psychiatric disorder Concurrent drug therapy monoamine oxidase inhibitor calcium channel blocker Need exclude concomitant medication ( see section 9.4.6.2 ) Use oxcarbazepine carbamazepine last 6 month randomisation visit Known hypersensitivity oxcarbazepine carbamazepine , metabolites Abuse alcohol , drug medication History relevant cardiac , renal , hepatic , endocrine , gastrointestinal , metabolic , hematologic oncology disorder Second thirddegree atrioventricular block correct pacemaker Relevant laboratory abnormality ( e.g. , Na+ &lt; 130 mmol/L , alanine ( ALT ) aspartate ( AST ) transaminase &gt; 2.0 time upper limit normal , white blood cell ( WBC ) count &lt; 3000 cells/mm3 ) Pregnancy , nurse inadequate contraception woman childbearing age ( oral contraception combine barrier method ) Participation clinical trial within last 2 month History noncompliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>BIA 2-093</keyword>
</DOC>